Difference between revisions of "Help:Contents"
m |
|||
| Line 21: | Line 21: | ||
==General information== | ==General information== | ||
| − | Class: Causes damage or degradation of PML-RAR alpha fusion protein, causes apoptosis-type changes in NB4 human promyelocytic leukemia cells in vitro<ref name="insert">[http://www.drugbank.ca/system/fda_labels/DB01169.pdf?1265922813 Arsenic trioxide (Trisenox) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/arsenictrioxide.pdf Arsenic trioxide (Trisenox) package insert (locally hosted backup)]</ref> | + | Class/mechanism: Causes damage or degradation of PML-RAR alpha fusion protein, causes apoptosis-type changes in NB4 human promyelocytic leukemia cells in vitro<ref name="insert">[http://www.drugbank.ca/system/fda_labels/DB01169.pdf?1265922813 Arsenic trioxide (Trisenox) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/arsenictrioxide.pdf Arsenic trioxide (Trisenox) package insert (locally hosted backup)]</ref> |
<br>Route: IV | <br>Route: IV | ||
| − | <br>Extravasation: [[irritant]] | + | <br>Extravasation: [[irritant]] or no information |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
Revision as of 15:26, 29 November 2011
To be made: Style pages for
- chemotherapy regimens
- diseases
- clinical trials
How to cite a source:
- Place this information where you want the numeric citation to appear:
<ref>Put the link [http://webaddress.org "text for the link"] inside the ref tags</ref> - Make sure to put <references/> in the reference area at the bottom of the page.
Categories - use for regimens, perhaps for chemotherapies, drug classes
Template to be used for chemotherapies:
(strive for minimalism, focus on regimens)
General information
Class/mechanism: Causes damage or degradation of PML-RAR alpha fusion protein, causes apoptosis-type changes in NB4 human promyelocytic leukemia cells in vitro[1][2]
Route: IV
Extravasation: irritant or no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Regimens
Standard format will be:
<acronym (if any)> <generic drug1, generic drug2, generic drug3, etc.> (disease)